Figure 4
Figure 4. Modulation of BIM acetylation and reexpression with vorinostat in vitro. (A) Two representative sensitive (ALL-3 and-11) and resistant (ALL-2 and -19) xenografts were treated with vorinostat (5μM, 6 hours) in vitro and subjected to H3AcK9 ChIP analysis. (B) BIM mRNA expression was determined by RT2-PCR after treatment with vorinostat (5μM, 6 hours), dexamethasone (1μM, 4 hours), or both in combination and expressed as a fold of untreated controls relative to EF-1α internal control. (C) Protein expression of Bim after treatment with vorinostat (5μM, 6 hours), dexamethasone (1μM, 4 hours), or both in combination was evaluated by immunoblot analysis and expressed relative to Actin in 2 dexamethasone-resistant xenografts (ALL-2 and ALL-19). Splicing within a representative gel is indicated by dividing spaces.

Modulation of BIM acetylation and reexpression with vorinostat in vitro. (A) Two representative sensitive (ALL-3 and-11) and resistant (ALL-2 and -19) xenografts were treated with vorinostat (5μM, 6 hours) in vitro and subjected to H3AcK9 ChIP analysis. (B) BIM mRNA expression was determined by RT2-PCR after treatment with vorinostat (5μM, 6 hours), dexamethasone (1μM, 4 hours), or both in combination and expressed as a fold of untreated controls relative to EF-1α internal control. (C) Protein expression of Bim after treatment with vorinostat (5μM, 6 hours), dexamethasone (1μM, 4 hours), or both in combination was evaluated by immunoblot analysis and expressed relative to Actin in 2 dexamethasone-resistant xenografts (ALL-2 and ALL-19). Splicing within a representative gel is indicated by dividing spaces.

Close Modal

or Create an Account

Close Modal
Close Modal